Plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation

被引:11
作者
Furuya, Maiko [1 ]
Yamamoto, Izumi [1 ]
Kobayashi, Akimitsu [1 ]
Nakada, Yasuyuki [1 ]
Sugano, Naoki [1 ]
Tanno, Yudo [1 ]
Ohkido, Ichiro [1 ]
Tsuboi, Nobuo [1 ]
Yamamoto, Hiroyasu [2 ]
Yokoyama, Keitaro [1 ]
Yokoo, Takashi [1 ]
机构
[1] Jikei Univ, Div Nephrol & Hypertens, Dept Internal Med, Sch Med, Tokyo 1058471, Japan
[2] Atsugi City Hosp, Dept Internal Med, Atsugi, Kanagawa, Japan
关键词
acute antibody-mediated rejection; anti-DQ antibody; plasma cell-rich rejection; RISK; HLA;
D O I
10.1111/nep.12245
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We report a case of plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation. A 33-year-old man was admitted for an episode biopsy; he had a serum creatinine (S-Cr) level of 5.7mg/dL 1 year following primary kidney transplantation. Histological features included two distinct entities: (1) a focal, aggressive tubulointerstitial inflammatory cell (predominantly plasma cells) infiltration with moderate tubulitis; and (2) inflammatory cell infiltration (including neutrophils) in peritubular capillaries. Substantial laboratory examination showed that the patient had donor-specific antibodies for DQ4 and DQ6. Considering both the histological and laboratory findings, we diagnosed him with plasma cell-rich rejection accompanied by acute antibody-mediated rejection. We started 3 days of consecutive steroid pulse therapy three times every 2 weeks for the former and plasma exchange with intravenous immunoglobulin (IVIG) for the latter histological feature. One month after treatment, a second allograft biopsy showed excellent responses to treatment for plasma cell-rich rejection, but moderate, acute antibody-mediated rejection remained. Therefore, we added plasma exchange with IVIG again. After treatment, allograft function was stable, with an S-Cr level of 2.8mg/dL. This case report demonstrates the difficulty of the diagnosis of, and treatment for, plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation. We also include a review of the related literature.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 10 条
[1]   Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft [J].
Adrogue, Horacio E. ;
Soltero, Lihana ;
Land, Geoffrey A. ;
Ramanathan, Venkataraman ;
Truong, Luan D. ;
Suki, Wadi N. .
TRANSPLANTATION, 2006, 82 (04) :567-569
[2]   Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: Early treatment options for improving outcomes [J].
Chandrasekar, Pranatharthl ;
Ljungman, Per T. .
TRANSPLANTATION, 2008, 86 (02) :183-191
[3]   Plasma cell-rich acute renal allograft rejection [J].
Charney, DA ;
Nadasdy, T ;
Lo, AWH ;
Racusen, LC .
TRANSPLANTATION, 1999, 68 (06) :791-797
[4]   Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation [J].
DeVos, Jennifer M. ;
Gaber, A. Osama ;
Knight, Richard J. ;
Land, Geoffrey A. ;
Suki, Wadi N. ;
Gaber, Lillian W. ;
Patel, Samir J. .
KIDNEY INTERNATIONAL, 2012, 82 (05) :598-604
[5]   SUBSTANTIAL BENEFITS OF TISSUE MATCHING IN RENAL-TRANSPLANTATION [J].
GILKS, WR ;
BRADLEY, BA ;
GORE, SM ;
KLOUDA, PT .
TRANSPLANTATION, 1987, 43 (05) :669-674
[6]   The post-transplant lymphoproliferative disorder - a literature review [J].
Shroff, R ;
Rees, L .
PEDIATRIC NEPHROLOGY, 2004, 19 (04) :369-377
[7]   Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival [J].
Terasaki, P. I. ;
Ozawa, M. ;
Castro, R. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (02) :408-415
[8]  
TING A, 1980, LANCET, V2, P282
[9]   De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy [J].
Willicombe, Michelle ;
Brookes, Paul ;
Sergeant, Ruhena ;
Santos-Nunez, Eva ;
Steggar, Corinna ;
Galliford, Jack ;
Mclean, Adam ;
Cook, Terence H. ;
Cairns, Tom ;
Roufosse, Candice ;
Taube, David .
TRANSPLANTATION, 2012, 94 (02) :172-177
[10]   Antibody-Mediated Rejection After Alemtuzumab Induction: Incidence, Risk Factors, and Predictors of Poor Outcome [J].
Willicombe, Michelle ;
Roufosse, Candice ;
Brookes, Paul ;
Galliford, Jack W. ;
Mclean, Adam G. ;
Dorling, Anthony ;
Warrens, Anthony N. ;
Cook, Terry H. ;
Cairns, Tom D. ;
Taube, David .
TRANSPLANTATION, 2011, 92 (02) :176-182